FDA Grants Accelerated Approval to Iberdomide for Relapsed or Refractory Multiple Myeloma

The FDA has granted accelerated approval to iberdomide (Zenbexus, Bristol-Myers Squibb Company) in combination with daratumumab and hyaluronidase-fihj and dexamethasone. This combination therapy is for adults with relapsed or refractory multiple myeloma (RRMM) who have received at least one prior line of therapy, including a proteasome inhibitor and an immunomodulatory agent. Iberdomide is the first approved cereblon E3 ligase modulator (CELMoD) agent, introducing a novel oral drug class to the myeloma treatment landscape.